Summary of the effects of the various drugs used to characterise second messenger pathways on the light parameters of A. filiformis, O. aranea and O. californica
| . | . | Effect . | . | . | ||
|---|---|---|---|---|---|---|
| Drug . | Activity . | A. filiformis . | O. aranea . | O. californica . | ||
| db-cGMP | cGMP analogue (↑ cGMP) | − | 0 | 0 | ||
| Na nitro | Guanylyl cyclase activator (↑ cGMP) | 0 | 0 | 0 | ||
| db-cAMP | cAMP analogue (↑ cAMP) | 0 | 0 | 0 | ||
| Forskolin | Adenylyl cyclase activator (↑ cAMP) | 0 | 0 | 0/+ | ||
| MDL-12,330A | Adenylyl cyclase inhibitor (↓ cAMP) | − | − | − | ||
| SQ22,536 | Adenylyl cyclase inhibitor (↓ cAMP) | − | − | − | ||
| IBMX | Phosphodiesterase inhibitor (↑ cGMP and cAMP) | − | 0 | 0 | ||
| Pentoxifylline | Phosphodiesterase inhibitor (↑ cGMP and cAMP) | 0 | 0 | 0 | ||
| U-73122 | Phospholipase C inhibitor (↓ IP3 and DAG) | − | − | − | ||
| U-73343 | Inactive analogue of U-73122 | − | − | − | ||
| GF 109203X | Protein kinase C inhibitor | 0 | 0 | 0 | ||
| . | . | Effect . | . | . | ||
|---|---|---|---|---|---|---|
| Drug . | Activity . | A. filiformis . | O. aranea . | O. californica . | ||
| db-cGMP | cGMP analogue (↑ cGMP) | − | 0 | 0 | ||
| Na nitro | Guanylyl cyclase activator (↑ cGMP) | 0 | 0 | 0 | ||
| db-cAMP | cAMP analogue (↑ cAMP) | 0 | 0 | 0 | ||
| Forskolin | Adenylyl cyclase activator (↑ cAMP) | 0 | 0 | 0/+ | ||
| MDL-12,330A | Adenylyl cyclase inhibitor (↓ cAMP) | − | − | − | ||
| SQ22,536 | Adenylyl cyclase inhibitor (↓ cAMP) | − | − | − | ||
| IBMX | Phosphodiesterase inhibitor (↑ cGMP and cAMP) | − | 0 | 0 | ||
| Pentoxifylline | Phosphodiesterase inhibitor (↑ cGMP and cAMP) | 0 | 0 | 0 | ||
| U-73122 | Phospholipase C inhibitor (↓ IP3 and DAG) | − | − | − | ||
| U-73343 | Inactive analogue of U-73122 | − | − | − | ||
| GF 109203X | Protein kinase C inhibitor | 0 | 0 | 0 | ||
−, inhibition; 0, no effect; 0/+, positive effect on light production(↓ of kinetic parameters).